Thomas Bachelot

24.1k citations

241 papers · 8.4k indexed · 5 hit papers · h-index 41

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Cancer Research top 0.5%
- Breast Cancer Treatment Studies

Papers in

Oncology 185
- Cancer Treatment and Pharmacology 90
- HER2/EGFR in Cancer Research 66
- Lung Cancer Research Studies 21
Cancer Research 73
- Breast Cancer Treatment Studies 43
- Cancer Genomics and Diagnostics 25

Co-authors: Jean‐Yves Blay Isabelle Ray‐Coquard Mario Campone Isabelle Treilleux Christine Ménétrier‐Caux Claire Cropet Jean-Marc Ferrero Véronique Dièras
Journals: Journal of Clinical Oncology (65 papers)Cancer Research (30 papers)Annals of Oncology (26 papers)European Journal of Cancer (10 papers)Breast Cancer Research and Treatment (8 papers)
Partner nations: France United States United Kingdom

In The Last Decade

Thomas Bachelot

230 papers receiving 8.3k citations

Hit Papers

5 papers align trajectories log scale

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 2024 · 53 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Medicine
2012 The Lancet Oncology
2012 Journal of Clinical Oncology
2009 Cancer Research
2009 Cancer Research

Peers

Countries citing papers authored by Thomas Bachelot

Since Specialization

Citations

This map shows the geographic impact of Thomas Bachelot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bachelot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bachelot more than expected).

Fields of papers citing papers by Thomas Bachelot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Bachelot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bachelot. The network helps show where Thomas Bachelot may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Bachelot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Bachelot Line = papers co-authored together Thomas Bachelot links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach NAR Cancer ·Anne-Laure Vitte, Florent Chuffart, Emmanuelle Jacquet, D Müller-Mahn, Mireille Mousseau, T. Sorlie, Séverine Tabone‐Eglinger, Thomas Bachelot, Sophie Rousseaux, Saadi Khochbin, Ekaterina Bourova-Flin	2025	0
2	412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA ESMO Open ·T. De La Motte Rouge, Omer Kazmi, И. В. Пак, Jean‐Christophe Grenier, Yu Jin Im, 하태근, M. Žiška, 惟介山本, Gulmira Baiterekova, Dylan Christiano, Jérôme Lemonnier, Taixuan Wan, Thomas Bachelot, Bharat Karnad	2025	0
3	Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data Clinical Cancer Research ·Frederick M. Howard, Peter A. Fasching, Cesar A. Santa‐Maria, Elgene Lim, Joseph A. Sparano, Maryam B. Lustberg, Thomas Bachelot, Oleg Blyuss, Christine Brezden‐Masley, Yeon Hee Park, Наталья Владимировна Копылова, 인병억, Elham Vosoughi, Christoph Kurz, Patricia Domínguez Castro, Pedram Razavi	2025	1
4	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. Journal of Clinical Oncology ·Erika Hamilton, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, Michele Autore, José Luiz Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, Megan Roegner, Shahid Ashfaque, 実米口, Anton Egorov, Javier Cortés	2024	5
5	p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane British Journal of Cancer ·Hélène Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bièche, Mario Campone, Anne Patsouris, Mónica Arnedos, Paul Cottu, Jean-Philippe Jacquin, Florence Dalenc, W.H. Shon, Nicolas Servant, Valéry Attignon, Étienne Rouleau, Alain Morel, 徐国雄李敏, Marta Jimenez, Fabrice André, Thomas Bachelot	2024	0
6	A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study JMIR Cancer ·小野ともえ, A. Perloff, Tong Jun Qv, Thomas Bachelot, Qijin Sun, Yang Sikun, Armelle Dufresne, Dr. Muhammad Ali Khan, Olivier Trédan, Kwang-Min Choe, Pierre-Étienne Heudel	2023	2
7	Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial Journal of Clinical Oncology ·François‐Clément Bidard, Nicolas Kiavué, William Jacot, Thomas Bachelot, Sylvain Dureau, Hugues Bourgeois, Anthony Gonçalvès, Étienne Brain, Sylvain Ladoire, Florence Dalenc, Joseph Gligorov, Luís Teixeira, Desy Ratnasari, Jean-Marc Ferrero, Delphine Loirat, Luc Cabel, Amir Kadi, Véronique Dièras, Catherine Alix‐Panabières, Jean‐Yves Pierga	2023	28
8	De Novo Oligometastatic Breast Cancer Journal of Clinical Oncology ·Lajos Pusztai, Andrea Vazquez Maldonado, Peter Dubsky, Thomas Bachelot, Anna M. Kirby, Barbro Linderholm, Julia White, Steven J. Chmura, Lisa A. Carey, Boon Chua, Kathy D. Miller	2023	3
9	Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer Oxidative Medicine and Cellular Longevity ·Lidia Delrieu, Marina Touillaud, Olivia Pérol, Magali Morelle, Agnès Martin, Christine M. Friedenreich, Pauline Mury, Armelle Dufresne, Thomas Bachelot, Courtnae Devane, Béatrice Fervers, Olivier Trédan, Vincent Pialoux	2021	18
10	Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and Number The Journal of Immunology ·Laurie Besson, Benoîte Méry, Magali Morelle, Yamila Rocca, Pierre-Étienne Heudel, Benoît You, Thomas Bachelot, Isabelle Ray‐Coquard, Marine Villard, Emily Charrier, François Parant, Sébastien Viel, Gwenaële Garin, Mathieu Béluse, David Pérol, Thierry Walzer, Olivier Trédan, Antoine Marçais	2021	9
11	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer Clinical Cancer Research ·Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, 純子西周, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders	2020	144
12	Physical activity preferences before and after participation in a 6‐month physical activity intervention among women with metastatic breast cancer European Journal of Cancer Care ·Lidia Delrieu, Jeff K. Vallance, Magali Morelle, Béatrice Fervers, Vincent Pialoux, Christine M. Friedenreich, Armelle Dufresne, Thomas Bachelot, Pierre-Étienne Heudel, Olivier Trédan, Olivia Pérol, Marina Touillaud	2019	15
13	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study JMIR mhealth and uhealth ·Lidia Delrieu, Vincent Pialoux, Olivia Pérol, Magali Morelle, Agnès Martin, Christine M. Friedenreich, Kajal Bhika, David Pérol, Emma Fransson, Harold José, J Cascajo, Armelle Dufresne, Thomas Bachelot, Pierre-Étienne Heudel, Marina Touillaud, Olivier Trédan, Béatrice Fervers	2019	40
14	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial JMIR Research Protocols ·Lidia Delrieu, Olivia Pérol, Béatrice Fervers, Christine M. Friedenreich, Jeff K. Vallance, Kajal Bhika, David Pérol, Brice Canada, J Cascajo, Armelle Dufresne, Thomas Bachelot, Pierre-Étienne Heudel, Olivier Trédan, Marina Touillaud, Vincent Pialoux	2018	20
15	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations Cancer Research ·Yu Fu, Cécile Jovelet, Thomas Filleron, Marion Pedrero, Nelly Motté, Yannick Boursin, أ.د. سعد حسن كاظم, Christophe Massard, Mario Campone, Christelle Lévy, Véronique Dièras, Thomas Bachelot, Julie Garrabey, Jean‐Charles Soria, Ludovic Lacroix, Fabrice André, Céline Lefèbvre	2016	11
16	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells Cancer Research ·Julien Faget, Nathalie Bendriss‐Vermare, Michael Gobert, Isabelle Durand, Daniel Olive, Cathy Biota, Thomas Bachelot, Isabelle Treilleux, Sophie Goddard‐Léon, Emilie Lavergne, Sylvie Chabaud, Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	2012	159
17	Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression Cancer Research ·Vanja Sisirak, Julien Faget, Michael Gobert, Nadège Goutagny, Nelly Vey, Isabelle Treilleux, Sarah Renaudineau, Gaelle Poyet, Sana Intidhar Labidi‐Galy, Sophie Goddard‐Léon, Isabelle Durand, Isabelle Le Mercier, Agathe Bajard, Thomas Bachelot, Alain Puisieux, Isabelle Puisieux, Jean‐Yves Blay, Christine Ménétrier‐Caux, Christophe Caux, Nathalie Bendriss‐Vermare	2012	269
18	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer Bulletin du Cancer ·Julien Péron, Olivier Trédan, Isabelle Ray‐Coquard, Thomas Bachelot, Sana Intidhar Labidi‐Galy, Bertrand Favier, Isabelle Treilleux, Jean‐Paul Guastalla	2012	2
19	Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells Cancer Research ·Julien Faget, Cathy Biota, Thomas Bachelot, Michael Gobert, Isabelle Treilleux, Nadège Goutagny, Isabelle Durand, Sonsoles Collado, Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	2011	103
20	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome Cancer Research ·Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, Thomas Bachelot, Sophie Goddard‐Léon, Vanessa Arfi, Cathy Biota, Octavio Ávila Pérez, Isabelle Durand, Daniel Olive, Solène Perez, Nicolas Pasqual, Christelle Fauré, Isabelle Ray‐Coquard, Alain Puisieux, Christophe Caux, Jean‐Yves Blay, Christine Ménétrier‐Caux Hit paper breakdown →	2009	562

About Thomas Bachelot

Thomas Bachelot is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Family Practice and Radiology, Nuclear Medicine and Imaging, having authored 241 papers that have together received 8.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (90 papers), Advanced Breast Cancer Therapies (81 papers), HER2/EGFR in Cancer Research (66 papers), Breast Cancer Treatment Studies (43 papers), Cancer Genomics and Diagnostics (25 papers), PI3K/AKT/mTOR signaling in cancer (23 papers), Lung Cancer Treatments and Mutations (22 papers) and Lung Cancer Research Studies (21 papers). The work is most often cited by research in Oncology (5.8k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (3.0k citations), Immunology (1.8k citations) and Genetics (774 citations). Thomas Bachelot has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Jean‐Yves Blay, Isabelle Ray‐Coquard, Mario Campone, Isabelle Treilleux, Christine Ménétrier‐Caux, Claire Cropet, Jean-Marc Ferrero, Véronique Dièras, Jean‐Yves Pierga and Nathalie Bendriss‐Vermare. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact